Sandwalk joins the Pharmabiotic Research Institute (PRI) as an Incubator Member
The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 to support the development of microbiome-based medicines for the EU market, for the benefit of patients. It applies a unique ‘Share & Learn’ approach to overcome the complex and various regulatory challenges faced by the relevant stakeholders. Its overall mission is to facilitate the conversation between European regulators and Microbiome medicinal product developers and their partners, and to become the key network of stakeholders driving the new therapeutic and diagnostic innovation in the field of microbiome science.
This alliance comes after Sandwalk’s strategic partnership with General Inception, by which both companies will work together in the development of next-generation microbiome technologies. PRI membership will give Sandwalk access to key microbiome regulatory insight and will provide new companies in Sandwalk’s and General Inception’s portfolio with support on regulatory affairs to develop microbiome-based therapeutics and diagnostics.